No abstract

SummaryBackground A wide variety of both surgical and nonsurgical therapies is currently available for patients with skin cancer. Objectives This part of the EPIDERM (European Prevention Initiative for Dermatological Malignancies) project is aimed at the evaluation of the treatment preferences for skin cancer in eight countries of the European Union. Methods A multicentre hospital-based case-control study was carried out at dermatology departments in Finland, Germany, Greece, Italy, Malta, Poland, Scotland and Spain. Patients with skin cancer (basal cell carcinoma, actinic keratosis, squamous cell carcinoma, cutaneous malignant melanoma and Bowen disease) were consecutively enrolled between July 2008 and July 2010. Information on the study variables (sex, age, country, tumour type, anatomical location and treatment) was obtained from questionnaires designed by the EPIDERM project. Results In total, 1708 patients with skin cancer were included. Surgery was the first treatment option in 76AE5% of the patients (P = 0AE001). Actinic keratosis was the only tumour type in which nonsurgical treatment was more frequent than surgery (91AE4%). Tumours on the head were less likely to be surgically excised than those at other locations (odds ratio 0AE25, P = 0AE001). Simple excision or curettage was the most common surgical procedure (65AE4%), followed by graft and flaps (22AE4%). Cryotherapy was the most common nonsurgical option (52AE4%), followed by imiquimod (18AE0%), photodynamic therapy (PDT; 12AE0%), 5-fluorouracil (5-FU; 5AE7%), and diclofenac with hyaluronic acid (4AE0%). Conclusions Surgery remains the first-choice treatment of skin cancer. Regarding nonsurgical treatments, the conservative treatments available (imiquimod, PDT and diclofenac gel) have not yet exceeded the use of ablative options such as cryotherapy despite their accepted benefit of treating field cancerization.

positive in patients with fixed drug eruption when cultivating lymphocytes with the causative drug only. 14 Surprisingly, Gimenez-Camarasa et al. 15 reported in 1975 positive results when combining the lymphocyte culture, the causative drug and patient serum obtained at the acme of fixed drug eruption. For quinine, this has to be investigated further in the future.Whether these two cases should be considered fixed drug or fixed food eruptions is open to discussion: either are permissible since in both cases, the lesions were induced by a food containing small amounts of a well-known drug. Despite quinine's now diminished therapeutic importance and clinical use, the contribution of dietary quinine to clinical symptoms of a fixed drug eruption should be considered, and adequate testing should be performed.

Literature data regarding the impact of pandemic on psoriasis and the relationship between psoriasis and COVID-19 outcomes are emerging. [1][2][3][4][5][6][7][8] The main aim of this study was to evaluate the impact of COVID-19 on treatment maintenance, disease course, psychosocial status, and intention to vaccinate in patients with moderate to severe psoriasis under systemic treatment (biologic agents, conventional systemic